Uncategorized-EN
Short Course Of Preoperative Radiotherapy in Extremity Soft Tissue Sarcomas (SCOPES)
Agents: Radiotherapy Phase II Status Recruiting Sponsor The Netherlands Cancer Institute Further information:Â https://www.clinicaltrials.gov/ct2/show/NCT04425967?term=Short+Course+Of+Preoperative+Radiotherapy+in+Extremity+Soft+Tissue+Sarcomas&cond=sarcoma&draw=2&rank=1 WHO is the trial for? Newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area No regional and/or distant disease Overall health status of the patient has to be…
Read MoreSelinexor in Advanced Liposarcoma (SEAL)
Selinexor in Advanced Liposarcoma (SEAL) Agents: Selinexor Phase II/III Status Closed, active Sponsor Karyopharm Therapeutics Inc Further information: https://clinicaltrials.gov/ct2/show/NCT02606461 This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma (DDLS) WHO is the trial for? Patients of 12 years or older with confirmed DDLS Disease…
Read MoreMilademetan versus trabectedin in dedifferentiated liposarcoma (MANTRA)
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) Agents: Milademetan vs. Trabectedin Phase III Status Recruiting Sponsor Rain Therapeutics Inc. Further information: https://www.clinicaltrials.gov/ct2/show/NCT04979442?term=mantra&cond=sarcoma&draw=2&rank=1 This is a Phase 3 registration study evaluating the safety and efficacy of milademetan compared to trabectedin in patients with unresectable or metastatic, progressing dedifferentiated liposarcoma. WHO is the…
Read MoreDose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY) (2)
Agents: Radiotherapy Phase II Status Closed, active Sponsor The Netherlands Cancer Institute Further information: https://clinicaltrials.gov/ct2/show/NCT02106312 WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…
Read MoreVimseltinib for Tenosynovial Giant Cell Tumor (MOTION)
Trial name: Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT), MOTION study Agents: Vimseltinib vs. placebo Phase III Status Not recruiting, but active Sponsor Deciphera Pharmaceuticals This Phase 3 clinical study aims to evaluate the effectiveness of vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the…
Read MoreUnesbulin in Advanced Leiomyosarcoma (SUNRISELMS)
Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (SUNRISELMS) Agents: Unesbulin in combination with dacabazine Phase II/III Status Recruiting Sponsor PTC Therapeutics Further information: https://clinicaltrials.gov/ct2/show/NCT05269355 This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in patients with unresectable or metastatic, relapsed or refractory leiomyosarcoma (LMS) who have received at…
Read MorePalbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Ewing Sarcomas
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors incl. Ewing Sarcomas (phase II) Agents: Combination with irinotecan and temozolomide with or without palbociclib Phase II Status Closed for recruitment, but active Sponsor Pfizer Further information: https://clinicaltrials.gov/ct2/show/NCT03709680 This study is comparing the effectiveness of the study medicine palbociclib when taken in combination with chemotherapy medicines irinotecan…
Read MoreSTRASS Trial
Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma (STRASS) Agents: Radiation therapy followed by surgery vs. surgery alone Phase III Status Open, recruiting Sponsor European Organisation for Research and Treatment of Cancer – EORTC Further information Link zu Details (to be inserted) WHO is the trial…
Read MoreMitigate
The Mitigate Project Agents: A novel PET-CT tracer specifically developed to target cell surface receptors of GIST cells Phase I/IIa Status Open, recruiting Sponsor Medical University Innsbruck, European Union Further information: www.mitigate-project.eu WHO is the trial for? Patients with progressive disease who have at least been treated with imatinib are eligible The study addresses…
Read MoreCABO GIST
CABO GIST Agents: Cabozantinib Phase II Status Completed Sponsor EORTC Further information: https://clinicaltrials.gov/ct/show/NCT02216578 or http://www.eortc.org/research_field/clinical-detail/1317/ WHO is the trial for? Patients with metastatic GIST (histologically confirmed) and removed primary tumor Patients with progression during treatment of GIST (before or after surgery, with or without metastasis) with imatinib and sunitinib (but no further/other therapies) Overall…
Read More